ClinicalTrials.gg
RecruitingNCT06567522Updated Aug 22, 2024

Comparative Assessment of Effectiveness and Safety of L-ESPB Versus Absence of Locoregional Block in Hip Surgery

A Phase 4 interventional study of Lumbar Erector Spinae Plane Block. L bupivacaína 0.25% in Hip Fractures and Lumbar Erector Spinae Plane Block, sponsored by Hospital Álvaro Cunqueiro. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-22.

Sponsored by Hospital Álvaro Cunqueiro · Phase 4, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Hip Fractures with a site in Spain — 10 open to participants now, 10 under way, none of them phase 3. Hip Fractures · Spain.

Planned enrollment
18th of 38
180 · median 168
Started
2024
with 5 others
Phase 4
10 of 49
2 open now
Registered
42nd of 49
by date

Among the 49 studies in Hip Fractures with a site in Spain, this one is the 18th largest by planned enrollment of the 38 interventional ones that give a count, is one of 6 that started in 2024, is one of 10 in phase 4, and was the 42nd registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

10 of the 49 studies in Hip Fractures with a site in Spain are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Hip Fractures with a site in Spain, or all of them as a file.
02

Study summary

Hip surgery accounts for a high percentage of both emergency and elective surgical procedures in hospitals. Regardless of surgery being prescribed to treat a fracture or coxarthrosis, patients are usually elderly with multiple associated comorbidities. When faced with this patient profile, there is a tendency to undertreat pain for fear of the side effects and pharmacological interactions of conventional analgesic drugs.

Ultrasound-guided regional anesthesia applied in orthopedic and trauma surgery has been shown to reduce the doses of opioids and conventional analgesics, to ease deambulation and early recovery, to improve respiratory dynamics and to reduce vein thrombosis and pneumonias. Our study aims to verify whether L-ESP block is effective in the hip and proximal femur surgeries and allows to lower the dosage of opioids in these patients.

03

Conditions studied

  • Hip Fractures
  • Lumbar Erector Spinae Plane Block

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Both sexes over 18 years of age having undergone hip surgery
  • (classification system used by the American Society of Anesthesiologists where I is low anesthetic risk and IV is high risk)
  • Capacity to comprehend the principles of pain assessment using the VAS visual analogue scale
  • Previously signed an .

Exclusion criteria

Exclusion Criteria:

  • for the technique and/or the drugs used in this context
  • Technical inability to perform the block
  • Severe cognitive impairment or prior mental disabilities described in their medical records
  • Patients already included in other clinical trials.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    ESP-L

    After hip fracture surgery ultrasound-guided ESP-L shall be carried out at the L3-14 level with 30 mL of levobupivacaine 0.25%

    Drug: Lumbar Erector Spinae Plane Block. L bupivacaína 0.25%

  • No intervention
    No ESP-L

    Conventional intravenous analgesia after hip fracture surgery

Interventions

  • DrugLumbar Erector Spinae Plane Block. L bupivacaína 0.25%

    Ultrasound-guided ESP-L shall be carried out at the L3-14 level with 30 mL of levobupivacaine 0.25%

06

What researchers measure

Primary outcomes

  1. To compare the analgesic effectiveness and safety of lumbar ESP block versus absence of block after hip and proximal femur surgeries by means of the VAS scale with pain reduction of at least 1 point in the first two hours after surgery.

    Collect data on post-surgery pain using the Visual Analogue Scale (VAS).The VAS scale ranges from 0 to 10, with 0 being no pain and 10 being maximum pain.

    Time frame: 2 hours after surgery

Secondary outcomes

  1. Compare the analgesic postoperative needs after performing L-ESP block versus a control group of patients having undergone hip or proximal femur surgeries and the postoperative consumption of opioids in both groups

    Consumption of morphine (mg)

    Time frame: 12 hours postoperative

  2. Percentage of patients with technical ease to perform the esp-l block

    We will define the technical ease of the esp-l block from 1 to 3. 1 being good and when we are able to clearly distinguish anatomical structures in order to carry out the locoregional analgesia, 2 would be equivalent to regular, when these are sensed but not clearly defined structures and bad when we are not able to distinguish any anatomical structure that allows us to carry out the block.

    Time frame: 48 hours postoperative

  3. Patient satisfaction survey on pain management

    We will classify patients into two groups according to their satisfaction with pain management in the postoperative period of hip surgery. Being the group of patients who consider themselves satisfied with pain management when it meets their expectations and dissatisfied if the patients are discomforted with it.

    Time frame: 48 hours postoperative

  4. Describe de side effects of the lumbar ESP block and morphine

    pruritus, nausea, vomiting, erythema, hypotension

    Time frame: 48 hours postoperative

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Dec 2025, 18 months after the start.

Of 33 non-industry phase 4 interventional studies under Hip Fractures, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 54. This study's planned 18 months is below that.

Counting every sponsor, half of 33 studies reached it within 25 months; a quarter within 11 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2024
First posted
Aug 22, 2024
StartActual
Jun 8, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Aug 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06567522
Lead sponsor
Hospital Álvaro Cunqueiro
Responsible party
Sponsor
First posted
Aug 22, 2024
Start date
Jun 8, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Aug 22, 2024

Study contacts

Laura García Reza
Contact
laura.garcia.reza@sergas.es
626708239
Laura García Reza
principal investigator · Hospital Álvaro Cunqueiro

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion